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Cause for Concern?*Patrizio Lancellotti, MD, PHD,a,b Marie Moonen, MD, PHD,a Maurizio Galderisi, MDcI mmunotherapy is an expanding resource intreating cancer patients, with impressive benefi-cial effects on survival in several advanced ma-
lignancies (1). Cancer activates multiple mechanisms
that co-opt host–tumor immune interactions, thus
inducing immune evasion. Novel therapeutic ap-
proaches have been developed by manipulating and
engineering immune cells, which has created great
expectations in the oncology community. To date,
at least 2 immunotherapeutic strategies, checkpoint
inhibition and cellular therapy with autologous
chimeric antigen-receptor T cells (CAR-T cells), have
clearly demonstrated their efficacy in treating solid
tumors and in a few hematologic malignancies. In
contrast, checkpoint inhibitors can produce a wide
spectrum of immune-related adverse complications,
also involving the heart, and episodes of fulminant
myocarditis or fatal heart failure have been described
in patients treated with these drugs (2). Adverse
events related to CAR-T cells involve mainly
cytokine-related syndrome (CRS) and neurotoxicity
(3), but little is known about the occurrence of cardio-
vascular (CV) complications.SEE PAGE 3099The study by Alvi et al. (4) in this issue of the
Journal adds valuable information to this issueISSN 0735-1097/$36.00
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cells, most of whom had relapsed diffuse large B-
cell lymphoma (5). The definition of cardiotoxicity
was based on a troponin increase or a left ventricular
ejection fraction (LVEF) decrease compared to the
pre-treatment period. CV events were composites of
arrhythmias, decompensated heart failure, and CV
death. The study by Alvie et al. (4) clearly demon-
strated that cardiac damage and CV events represent
relatively frequent complications of CAR-T cell ther-
apy, as shown by 21% to 59% of the treated patients
who experienced cardiac damage, 12% of whom had
CV events and 4% of whom had cardiac-related death.
The present study pointed out several observations
that need commentary. First, CAR-T cell cardiotox-
icity occurred mainly in elderly patients (>60 years
old), often characterized by a high CV risk profile and
prior anticancer treatment including anthracyclines
and radiotherapy. Second, there was a strong associ-
ation between troponin elevation post-CAR-T cell
therapy (>0.03 ng/ml or high-sensitivity troponin
>14 ng/l) and subsequent CV events. Troponin
elevation was observed in 95% (16 of 17) of the pa-
tients experiencing CV events and was commonly
seen in patients with CRS development (defined as
the first appearance of fever after CAR-T cell therapy).
CRS of any grade (using a CRS grading system of 1 to
5) was common, occurring at a median of 5 days after
CAR-T cell therapy. Of note, an isolated elevation of
troponin without CRS was not associated with the
occurrence of CV events. Notably, a clinically signif-
icant decrease of LVEF (reduction of at least 10%
points to a value below 50%) was detected in 28% of
the patients treated with CAR-T cell, but only 29 of
the 135 patients had echocardiographic data pre- and
during CAR-T cell therapy. For this reason, a parallel
between troponin increase and LVEF reduction couldhttps://doi.org/10.1016/j.jacc.2019.10.028
FIGURE 1 Diagnostic Work-Up and Management of CAR–T Cell–Related Cardiotoxicity
BASELINE FOLLOW-UP














After a baseline comprehensive cardiovascular assessment, determination of troponin level within 5 days after CAR-T cell therapy should
guide patient management. If a significant rise in troponin is detected, echocardiography should be repeated, the CRS grade determined, and
tocilizumab initiated promptly. Timing of cardiological follow-up should be established in individual patients according to clinical judgment.
*Baseline assessment including a 24-h ECG and an inducible ischemia test, when needed. CAR-T ¼ chimeric antigen-receptor T cell;
CRS ¼ cytokine-related syndrome; CV ¼ cardiovascular; ECG ¼ electrocardiography; Echo ¼ echocardiography; LVEF ¼ left ventricular
ejection fraction.
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3110not be formally established, although a reduction in
LVEF was observed only in patients with increased
troponin and higher CRS grade after CAR-T cells were
administered. Lack of data for global longitudinal
strain and B-type natriuretic peptide release does not
support this relationship either. Also, all CV events
occurred in patients with a CRS grade $2, known to be
associated with significant organ toxicity. Finally, a
longer time between recognition of CRS and the
administration of tocilizumab was associated with an
increase in CV events.
The close relationships among CRS development,
troponin release, and the occurrence of CV events
represent a red flag that must be considered with
greater attention in this clinical setting. As observed
by Alvi et al. (4), the increase in troponin occurred in
patients with a CRS grade of at least $2, that is, in
patients with a higher degree of inflammation.
Troponin level is a reliable indicator of myocyte
injury in oncology patients with cardiotoxic effects of
anticancer drugs. In the case of CAR-T cell therapy,
the increase in troponin appeared to be primarily
related to the hypotension and tachycardia induced
by CRS. Treatment with CAR-T cells is associated with
a marked increase in interleukin (IL)-6. IL-6 exerts its
detrimental effect on several tissues, including
myocardium in CRS (5). This finding is entirely
consistent with the information obtained usingtocilizumab for the treatment of these patients.
Tocilizumab is a recombinant humanized anti-IL-6
monoclonal antibody that has been used primarily
in the treatment of rheumatoid arthritis. More
recently, it has demonstrated great use in success-
fully contrasting CRS and blunting its progression
from subclinical to clinical stages (6). It should be
noted that if the main anti-inflammatory properties of
corticosteroids are used to counteract the detrimental
CV effects of immune checkpoint inhibitors (2), then
the cardiotoxicity of CAR-T cells may be specifically
counterbalanced by tocilizumab. In the study by Alvi
et al. (4), early administration of tocilizumab was
associated with a significantly lower rate of CV
events, without preventing the antitumor effects of
CAR-T cells.
Together, these results point to major practical
implications that should be considered when using
CAR-T cells. First, results confirm the need for close
cooperation between oncologists/hematologists and
cardiologists in order to maximize the benefits of
innovative therapies for malignant tumors while
reducing and controlling the burden of CV complica-
tions, the characteristics and mechanisms of which
are often not yet well understood (7). Practically,
the combination of old age and evidence of
multiple pre-existing CV risk factors implies the
need for a preliminary, comprehensive cardiological
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3111work-up before the beginning of CAR-T cell therapy.
This work-up (Figure 1) should include biomarker
assessment (troponin and B-type natriuretic peptide),
a resting 12-lead electrocardiogram (ECG), and a
complete echocardiography-Doppler examination
(including global longitudinal strain) to identify car-
diac conditions representing the background of sub-
sequent CV complications. Values of LVEF should be
determined with good accuracy at baseline in patients
who had previously experienced potentially car-
diotoxic drugs, such as anthracyclines and radio-
therapy, and repeated periodically during CAR-T cell
therapy. In this respect, the use of 3D echocardiog-
raphy, which allows a more accurate and reproducible
assessment of LVEF and, therefore, is more suitable
for serial cardiac imaging evaluation, should not be
underestimated. In addition, the preliminary assess-
ment could include 24-h Holter ECG monitoring and
the search for inducible ischemia (stress imaging) in
patients with known or suspected coronary artery
disease and a high risk of developing episodes ofarrhythmia. During treatment, beyond clinical
assessment (i.e., fever), both troponin and LVEF
should be monitored. Any increase in troponin asso-
ciated with a CRS grade of $2 at day 5 after CAR-T cell
administration should prompt the initiation of car-
dioprotective therapy with tocilizumab. The same can
be done in case of a drop in LVEF. Conversely, an
isolated increase in troponin (a CRS grade of <2)
should not be treated, although caution is warranted
in the absence of additional data. Therefore, even if
there is a reason for concern, further studies
including more patients are needed to better under-
stand the relationship between CAR-T cells and car-
diovascular toxicity.
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